ACADVL

Very long-chain specific acyl-CoA dehydrogenase, mitochondrial · P49748 · ACADVL on Sugi Atlas →

135 patent compounds predicted against ACADVL, 113 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Tg100-115 (SCHEMBL360279)	1.00	1/20
Tg100-115 (SCHEMBL29361550)	1.00	1/20
Tg100-115 (SCHEMBL29369340)	1.00	1/20
Tg100-115 (SCHEMBL29411790)	1.00	1/20
Tg100-115 (SCHEMBL29506727)	1.00	1/20
Tg100-115 (SCHEMBL31238338)	1.00	1/20
Tg100-115 (SCHEMBL3537211)	0.97	1/20
Tg100-115 (SCHEMBL3539251)	0.97	1/20
Tg100-115 (SCHEMBL3539255)	0.97	1/20
SCHEMBL13403357	0.85	1/20
Tg100-115 (SCHEMBL3743017)	0.82	1/20
SCHEMBL1648630	0.81	1/20
SCHEMBL12198179	0.78	1/20
SCHEMBL3539253	0.72	1/20
SCHEMBL3743019	0.70	1/20
SCHEMBL13927978	0.69	1/20
SCHEMBL26503858	0.69	1/20
SCHEMBL3737062	0.68	1/20
SCHEMBL3734924	0.67	1/20
Hydrochloric Acid (SCHEMBL3537202)	0.66	1/20

Clinical trials — most relevant to ACADVL by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
CoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease	PHASE3	RECRUITING
Bezafibrate Trial in CPT2 Deficiency	PHASE3	UNKNOWN
Effect of Bezafibrate on Muscle Metabolism in Patients With Fatty Acid Oxidation Defects	PHASE2	COMPLETED
Acetylcarnitine and Insulin Sensitivity	PHASE2	COMPLETED
The Effects of Coenzyme A Combined With Abiraterone on Patients With CRPC	PHASE1/PHASE2	UNKNOWN
Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) and Parkinson's Disease (PD) Patients	PHASE2	COMPLETED
Atorvastatin, L-Carnitine and Non-Alcoholic Steatohepatitis	PHASE2	UNKNOWN
Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease	PHASE2	COMPLETED
Autologous Hematopoietic Stem Cell Gene Therapy for Metachromatic Leukodystrophy and Adrenoleukodystrophy	PHASE1/PHASE2	UNKNOWN
Efficacy and Safety of the Treatment of Pyruvate Dehydrogenase Deficiency Patients With Glycerol Phenylbutyrate (RAVICTI)	PHASE2	RECRUITING
Fatty Acid Oxidation Defects and Insulin Sensitivity	nan	COMPLETED
Effects of Parenteral L-carnitine Supplementation in Premature Neonates	nan	COMPLETED
Nutritional Therapy of the Deficits of Oxidation Mitochondrial of the Fatty Acids	nan	COMPLETED
Lifestyle Intervention in Preparation for Pregnancy (LIPP)	nan	COMPLETED
Fasting Tolerance in MCADD-infants	nan	UNKNOWN
Longitudinal Study of Mitochondrial Hepatopathies	nan	SUSPENDED
GDF-15 as a Biomarker for Mitochondrial Disease	nan	COMPLETED
Systemic Biomarkers of Brain Injury From Hyperammonemia	nan	RECRUITING
Metabolic Effects of Medium-Chain Fatty Acids in Patients With Medium-Chain Acyl-CoA Dehydrogenase Deficiency and Healthy Individuals	nan	RECRUITING
Compassionate Use of Triheptanoin (C7) for Inherited Disorders of Energy Metabolism	nan	NO_LONGER_AVAILABLE
A Prospective Study of the Disease Characteristics of Adult Patients With Long Chain Fatty Acid Oxidation Disorders	nan	COMPLETED
Nephroprotective Effects of Carnitine and (PDE5) Inhibitor Agent Against Contrast Media-induced Nephropathy (CMN)	nan	UNKNOWN
Acute Nutritional Ketosis in VLCAD Deficiency	nan	COMPLETED
Expanded Access to Triheptanoin	nan	AVAILABLE
Fatty Acid Oxidation Disorders & Body Weight Regulation Grant	nan	COMPLETED
Effects of Mixed Exercise Regime and L-Carnitine Supplementation in HIV Patients on HAART	nan	WITHDRAWN
Effect of Nutritional Supplementation and Pulmonary Rehabilitation on the Clinical Status of HF and COPD	nan	UNKNOWN
Effects of PPAR Ligands on Ectopic Fat Accumulation and Inflammation	nan	COMPLETED
McArdle Disease Treatment by Ketogenic Diet	nan	COMPLETED
Effects of L-Carnitine on Postprandial Clearance of Triglyceride-rich Lipoproteins in HIV Patients on HAART	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a ACADVL binder may also engage these)

Protein	Name	Similarity
Q8HXY7	—	1.000	Q8HXY7 →
P48818	—	1.000	P48818 →
P45953	—	0.996	P45953 →
P50544	—	0.996	P50544 →
ACAD9	Complex I assembly factor ACAD9, mitochondrial	0.987	landscape →
B1WC61	—	0.986	B1WC61 →
Q8JZN5	—	0.984	Q8JZN5 →
Q9D7B6	—	0.977	Q9D7B6 →
Q0NXR6	—	0.973	Q0NXR6 →
Q9UKU7	—	0.970	Q9UKU7 →
Q96329	—	0.969	Q96329 →
Q29554	—	0.965	Q29554 →
HADHA	Trifunctional enzyme subunit alpha, mitochondrial	0.964	landscape →
Q64428	—	0.962	Q64428 →
Q8BMS1	—	0.959	Q8BMS1 →
Q54IM8	—	0.958	Q54IM8 →
Q5RAS0	—	0.958	Q5RAS0 →
Q3ZBF6	—	0.957	Q3ZBF6 →
Q9NUZ1	—	0.956	Q9NUZ1 →
P16219	—	0.955	P16219 →
PC	Pyruvate carboxylase, mitochondrial	0.955	landscape →
Q60HD7	—	0.955	Q60HD7 →
Q9DBT9	—	0.955	Q9DBT9 →
Q9UI17	—	0.955	Q9UI17 →
PHGDH	D-3-phosphoglycerate dehydrogenase	0.954	landscape →
Q5R4R2	—	0.954	Q5R4R2 →
Q9YH58	—	0.953	Q9YH58 →
Q9RYG9	—	0.953	Q9RYG9 →
Q61753	—	0.953	Q61753 →
A0AAD6NFV5	—	0.952	A0AAD6NFV5 →